ClinicalTrials.gg
RecruitingNCT04440267Updated Aug 6, 2025

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

A Phase 2 interventional study of vincristine and daunorubicin in Acute Leukemia of Ambiguous Lineage, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Study summary

In this prospective, single arm, open label, clinical trial, a total of 50 acute leukemia of ambiguous lineage patients will be enrolled. Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) after CR . Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors. The purpose of current study is to evaluate the clinical efficacy of ALL-based chemotherapy,effect of genetic abnormality and minimal residual disease (MRD) on prognosis in patients with acute leukemia of ambiguous lineage.

02

Conditions studied

  • Acute Leukemia of Ambiguous Lineage
03

In context

Leukemia, Biphenotypic, Acute

246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 185 interventional studies indexed under Leukemia, Biphenotypic, Acute.

Browse Leukemia, Biphenotypic, Acute studies →

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged above 14 years with acute leukemia of ambiguous lineage .
  2. (ECOG) Performance status 2.
  3. Adequate end organ function as defined by: Total ≤ 1.5 x (ULN); serum glutamic-oxaloacetic transaminase() and serum glutamic pyruvic transaminase(SGPT) ≤ 2.5 x ULN; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; Patients must have adequate cardiac function ( ≥ 45 % on Multiple Gated Acquisition (MUGA) scan).
  4. Patients must have the following laboratory values (≥ lower limit of normal (LLN) or corrected to within normal limits with supplements prior to the first dose of study medication.): Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN
  5. Patients should sign form.

Exclusion criteria

Exclusion Criteria:

  1. Impaired cardiac function:

    Long syndrome or a known family history of long QT syndrome; resting brachycardia (\<50 beats per minute); \< 45 % on MUGA scan. Corrected QT (QTc) interval > 450 msec on baseline (using the QTcF formula). If QTcF interval>450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc. Myocardial infarction within 12 months prior to starting study; other clinically significant heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias).

  2. Other concurrent severe and/or uncontrolled medical conditions:

    Patients with another primary malignant disease, except those that do not currently require treatment; acute or chronic liver, pancreatic or severe renal disease; another severe and/or life-threatening medical disease.

  3. Patients who are: (a) pregnant and (b) breast feeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    single arm

    Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) in CR. Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors.

    Drug: vincristine · Drug: daunorubicin · Drug: cyclophosphamide · Drug: L-Asparaginase · Drug: prednisone · Drug: mercaptopurine · Drug: methotrexate · Drug: dexamethasone · Drug: Tyrosine kinase inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    From the date of diagnosis until the date of death from any cause,

    Time frame: up to 5 years

Secondary outcomes

  1. Relapse free survival (RFS)

    From the date of CR until the date of relapse or death

    Time frame: up to 5 years

  2. The complete remission (CR) rate

    Incidence of complete remission after induction chemotherapy

    Time frame: up to 2.5 years

  3. Mortality within 60 days

    Proportion of patients died within 60 days

    Time frame: up to 60 days

Other outcomes

  1. Chromosomal abnormalities detected by G-banding

    Time frame: Baseline

  2. Fusion genes detected by polymerase chain reaction

    Time frame: Baseline

  3. Mutations detected by next-generation sequencing

    Time frame: Baseline

  4. Minimal residual disease(MRD)

    The presence of small numbers of leukemic cells detected by the flow cytometry after remission

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • HBDH
    Tianjin, Tianjin Municipality 300020, China
    Recruiting
    • Hui Wei · Contact
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jun 2026, 71 months after the start.

Of 42 phase 2 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 153. This study's planned 71 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2020
First posted
Jun 19, 2020
StartActual
Jul 8, 2020
Primary completionEst.
Jun 20, 2026
CompletionEst.
Dec 20, 2027
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04440267
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Jul 8, 2020
Primary completion
Jun 20, 2026 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Aug 6, 2025

Study contacts

Jianxiang Wang, Dr
Contact
wangjx@ihcams.ac.cn
86-22-23909120

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vincristine · Daunorubicin · Cyclophosphamide · Asparaginase · Prednisone · Mercaptopurine · Methotrexate · Dexamethasone · Tyrosine kinase inhibitors (TKIs)

Start the discussion